RecruitingMitral Valve Regurgitation
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Eligible age
18+ yrs
Accepts
All genders
Locations
29 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Sponsor: Medtronic Cardiovascular
You may qualify if…
- ✓ Moderate to severe or severe symptomatic mitral regurgitation
- ✓ Local site multidisciplinary heart team experienced in mitral valve therapies agrees that the subject is unsuitable for treatment with approved transcatheter repair or conventional mitral valve intervention
You may not qualify if…
- ✕ prior transcatheter mitral valve procedure with device currently implanted
- ✕ anatomic contraindications
- ✕ prohibitive mitral annular calcification
- ✕ left ventricular ejection fraction \<25%
- ✕ need for emergent or urgent surgery
- ✕ hemodynamic instability
Where it's recruiting
Alabama
Birmingham
Arizona
Phoenix
California
La Jolla · Los Angeles · Mountain View · San Francisco …
Connecticut
Hartford · New Haven
District of Columbia
Washington D.C.
Florida
Atlantis · Clearwater · Fort Myers · Gainesville …
Georgia
Atlanta
Illinois
Chicago
Iowa
Des Moines
Kansas
Kansas City
Maryland
Baltimore
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT03242642 · last updated 2026-05-19